However, the prospect of overt AR stimulation, even transiently, in the treatment of localized prostate cancer poses difficulties in clinical implementation given the dependence on and stimulation of prostate cancer growth from AR signaling. The gene discussed is AR; the disease is Familial prostate cancer.